Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.

Rad Pour S, Morikawa H, Kiani NA, Gomez-Cabrero D, Hayes A, Zheng X, Pernemalm M, Lehtiö J, Mole DJ, Hansson J, Eriksson H, Tegnér J.

Front Oncol. 2020 Feb 3;10:51. doi: 10.3389/fonc.2020.00051. eCollection 2020.

2.

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma.

Melief J, Pico de Coaña Y, Maas R, Fennemann FL, Wolodarski M, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2020 Jan 17. doi: 10.1007/s00262-019-02476-9. [Epub ahead of print]

PMID:
31953577
3.

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.

Wickström SL, Lövgren T, Volkmar M, Reinhold B, Duke-Cohan JS, Hartmann L, Rebmann J, Mueller A, Melief J, Maas R, Ligtenberg M, Hansson J, Offringa R, Seliger B, Poschke I, Reinherz EL, Kiessling R.

Front Immunol. 2019 Dec 11;10:2766. doi: 10.3389/fimmu.2019.02766. eCollection 2019.

4.

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.

Das I, Gad H, Bräutigam L, Pudelko L, Tuominen R, Höiom V, Almlöf I, Rajagopal V, Hansson J, Helleday T, Egyházi Brage S, Warpman Berglund U.

Cell Death Differ. 2020 Jan 9. doi: 10.1038/s41418-019-0488-1. [Epub ahead of print]

PMID:
31919461
5.

Leadership in specialist palliative home care teams: A qualitative study.

Klarare A, Lind S, Hansson J, Fossum B, Fürst CJ, Lundh Hagelin C.

J Nurs Manag. 2020 Jan;28(1):102-111. doi: 10.1111/jonm.12902. Epub 2019 Dec 23.

PMID:
31868284
6.

Droplet leaping governs microstructured surface wetting.

Yada S, Bagheri S, Hansson J, Do-Quang M, Lundell F, van der Wijngaart W, Amberg G.

Soft Matter. 2019 Dec 14;15(46):9528-9536. doi: 10.1039/c9sm01854a. Epub 2019 Nov 13.

PMID:
31720679
7.

What happened and why? A programme theory-based qualitative evaluation of a healthcare-academia partnership reform in primary care.

Uvhagen H, Hasson H, Hansson J, von Knorring M.

BMC Health Serv Res. 2019 Nov 1;19(1):785. doi: 10.1186/s12913-019-4665-1.

8.

Implementation of a national policy for improving health and social care: a comparative case study using the Consolidated Framework for Implementation Research.

Strehlenert H, Hansson J, Nyström ME, Hasson H.

BMC Health Serv Res. 2019 Oct 22;19(1):730. doi: 10.1186/s12913-019-4591-2.

9.

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Das I, Wilhelm M, Höiom V, Franco Marquez R, Costa Svedman F, Hansson J, Tuominen R, Egyhàzi Brage S.

Cell Death Dis. 2019 Sep 10;10(9):663. doi: 10.1038/s41419-019-1875-8.

10.

Radiographers' perspectives' on Visual Grading Analysis as a scientific method to evaluate image quality.

Precht H, Hansson J, Outzen C, Hogg P, Tingberg A.

Radiography (Lond). 2019 Oct;25 Suppl 1:S14-S18. doi: 10.1016/j.radi.2019.06.006. Epub 2019 Aug 2.

PMID:
31481182
11.
12.

Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.

Rad Pour S, Morikawa H, Kiani NA, Yang M, Azimi A, Shafi G, Shang M, Baumgartner R, Ketelhuth DFJ, Kamleh MA, Wheelock CE, Lundqvist A, Hansson J, Tegnér J.

Sci Rep. 2019 Aug 21;9(1):12150. doi: 10.1038/s41598-019-48635-x.

13.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221. No abstract available.

14.

Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells.

Li H, Lim HC, Zacharaki D, Xian X, Kenswil KJ, Bräunig S, Raaijmakers MH, Woods NB, Hansson J, Scheding S.

Haematologica. 2019 Aug 1. pii: haematol.2019.216648. doi: 10.3324/haematol.2019.216648. [Epub ahead of print]

15.

Activation of neuronal genes via LINE-1 elements upon global DNA demethylation in human neural progenitors.

Jönsson ME, Ludvik Brattås P, Gustafsson C, Petri R, Yudovich D, Pircs K, Verschuere S, Madsen S, Hansson J, Larsson J, Månsson R, Meissner A, Jakobsson J.

Nat Commun. 2019 Jul 18;10(1):3182. doi: 10.1038/s41467-019-11150-8.

16.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.

PMID:
31160251
17.

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Taylor NJ, Mitra N, Qian L, Avril MF, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Gruis NA, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard AL, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Yang XR, Newton-Bishop JA, Kanetsky PA; GenoMEL Study Group.

J Am Acad Dermatol. 2019 Aug;81(2):386-394. doi: 10.1016/j.jaad.2019.01.079. Epub 2019 Feb 5.

PMID:
30731170
18.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A.

Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448.

PMID:
30698147
19.

Team type, team maturity and team effectiveness in specialist palliative home care: an exploratory questionnaire study.

Klarare A, Hansson J, Fossum B, Fürst CJ, Lundh Hagelin C.

J Interprof Care. 2019 Sep-Oct;33(5):504-511. doi: 10.1080/13561820.2018.1551861. Epub 2018 Nov 28.

PMID:
30485125
20.

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.

Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, Pivarcsi A, Eriksson H.

PLoS One. 2018 Nov 6;13(11):e0206942. doi: 10.1371/journal.pone.0206942. eCollection 2018.

21.

High-Yield Passive Plasma Filtration from Human Finger Prick Blood.

Hauser J, Lenk G, Hansson J, Beck O, Stemme G, Roxhed N.

Anal Chem. 2018 Nov 20;90(22):13393-13399. doi: 10.1021/acs.analchem.8b03175. Epub 2018 Nov 8.

PMID:
30379058
22.

Actions helping expressed or anticipated needs: Patients with advanced cancer and their family caregivers' experiences of specialist palliative home care teams.

Klarare A, Rasmussen BH, Fossum B, Hansson J, Fürst CJ, Lundh Hagelin C.

Eur J Cancer Care (Engl). 2018 Nov;27(6):e12948. doi: 10.1111/ecc.12948. Epub 2018 Oct 9.

PMID:
30298967
23.

Reinforcement of variability facilitates learning in humans.

Hansson J, Neuringer A.

J Exp Anal Behav. 2018 Nov;110(3):380-393. doi: 10.1002/jeab.475. Epub 2018 Oct 9.

PMID:
30298690
24.

Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.

Thrane K, Eriksson H, Maaskola J, Hansson J, Lundeberg J.

Cancer Res. 2018 Oct 15;78(20):5970-5979. doi: 10.1158/0008-5472.CAN-18-0747. Epub 2018 Aug 28.

25.

Comparative Secretome Analyses of Primary Murine White and Brown Adipocytes Reveal Novel Adipokines.

Ali Khan A, Hansson J, Weber P, Foehr S, Krijgsveld J, Herzig S, Scheideler M.

Mol Cell Proteomics. 2018 Dec;17(12):2358-2370. doi: 10.1074/mcp.RA118.000704. Epub 2018 Aug 22.

26.

The risk of graft loss 5 years after kidney transplantation is increased if cold ischemia time exceeds 14 hours.

Hansson J, Mjörnstedt L, Lindnér P.

Clin Transplant. 2018 Sep;32(9):e13377. doi: 10.1111/ctr.13377. Epub 2018 Aug 31.

PMID:
30098052
27.

Enhancing policy implementation to improve healthcare practices: The role and strategies of hybrid national-local support structures.

Granström E, Hansson J, Sparring V, Brommels M, Nyström ME.

Int J Health Plann Manage. 2018 Oct;33(4):e1262-e1278. doi: 10.1002/hpm.2617. Epub 2018 Aug 9.

PMID:
30091487
28.

Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients.

Ahlén Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M, Lundgren C, Holmström B, Palmqvist K, Hansson J, Alamdari F, Huge Y, Aljabery F, Riklund K, Winerdal ME, Krantz D, Zirakzadeh AA, Marits P, Sjöholm LK, Sherif A, Winqvist O.

Clin Epigenetics. 2018 Aug 3;10(1):102. doi: 10.1186/s13148-018-0536-6.

29.

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9.

PMID:
30069041
30.

Leading top-down implementation processes: a qualitative study on the role of managers.

Uvhagen H, Hasson H, Hansson J, von Knorring M.

BMC Health Serv Res. 2018 Jul 18;18(1):562. doi: 10.1186/s12913-018-3360-y.

31.

Understanding the dynamics of sustainable change: A 20-year case study of integrated health and social care.

Klinga C, Hasson H, Andreen Sachs M, Hansson J.

BMC Health Serv Res. 2018 Jun 4;18(1):400. doi: 10.1186/s12913-018-3061-6.

32.

Exploring the potential of a multi-level approach to improve capability for continuous organizational improvement and learning in a Swedish healthcare region.

Nyström ME, Höög E, Garvare R, Andersson Bäck M, Terris DD, Hansson J.

BMC Health Serv Res. 2018 May 24;18(1):376. doi: 10.1186/s12913-018-3129-3.

33.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.

Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

34.

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.

Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R, Garcia-Ruiz C, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J, Hagström-Andersson AK.

Nat Commun. 2018 May 2;9(1):1770. doi: 10.1038/s41467-018-04180-1.

35.

Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells.

Guzzi N, Cieśla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, Pimková K, Sommarin MNE, Munita R, Lubas M, Lim Y, Okuyama K, Soneji S, Karlsson G, Hansson J, Jönsson G, Lund AH, Sigvardsson M, Hellström-Lindberg E, Hsieh AC, Bellodi C.

Cell. 2018 May 17;173(5):1204-1216.e26. doi: 10.1016/j.cell.2018.03.008. Epub 2018 Apr 5.

36.

Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.

Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O.

Cancer Immunol Res. 2018 May;6(5):528-538. doi: 10.1158/2326-6066.CIR-17-0466. Epub 2018 Mar 27.

37.

Capillary pumping independent of the liquid surface energy and viscosity.

Guo W, Hansson J, van der Wijngaart W.

Microsyst Nanoeng. 2018 Mar 26;4:2. doi: 10.1038/s41378-018-0002-9. eCollection 2018.

38.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.

Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.

39.

Factors influencing early stage healthcare-academia partnerships.

Uvhagen H, von Knorring M, Hasson H, Øvretveit J, Hansson J.

Int J Health Care Qual Assur. 2018 Feb 12;31(1):28-40. doi: 10.1108/IJHCQA-11-2016-0178.

PMID:
29504843
40.

Comprehensive Proteomic Characterization of Ontogenic Changes in Hematopoietic Stem and Progenitor Cells.

Jassinskaja M, Johansson E, Kristiansen TA, Åkerstrand H, Sjöholm K, Hauri S, Malmström J, Yuan J, Hansson J.

Cell Rep. 2017 Dec 12;21(11):3285-3297. doi: 10.1016/j.celrep.2017.11.070.

41.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
42.

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. Erratum in: Nature. 2018 Aug;560(7718):E28.

PMID:
29144447
43.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J.

Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.

44.

Injury induced expression of caveolar proteins in human kidney tubules - role of megakaryoblastic leukemia 1.

Krawczyk KM, Hansson J, Nilsson H, Krawczyk KK, Swärd K, Johansson ME.

BMC Nephrol. 2017 Oct 24;18(1):320. doi: 10.1186/s12882-017-0738-8.

45.

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.

Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406.

46.

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Falkenius J, Johansson H, Tuominen R, Frostvik Stolt M, Hansson J, Egyhazi Brage S.

BMC Cancer. 2017 Aug 29;17(1):584. doi: 10.1186/s12885-017-3577-x.

47.

Fear or food - abundance of red fox in relation to occurrence of lynx and wolf.

Wikenros C, Aronsson M, Liberg O, Jarnemo A, Hansson J, Wallgren M, Sand H, Bergström R.

Sci Rep. 2017 Aug 22;7(1):9059. doi: 10.1038/s41598-017-08927-6.

48.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group.

J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.

49.

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.

Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V.

J Am Acad Dermatol. 2017 Nov;77(5):893-901. doi: 10.1016/j.jaad.2017.05.050. Epub 2017 Aug 14.

PMID:
28818438
50.

Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.

Lindgren D, Eriksson P, Krawczyk K, Nilsson H, Hansson J, Veerla S, Sjölund J, Höglund M, Johansson ME, Axelson H.

Cell Rep. 2017 Aug 8;20(6):1476-1489. doi: 10.1016/j.celrep.2017.07.043.

Supplemental Content

Loading ...
Support Center